第一创业证券承销保荐有限责任公司 关于凯莱英医药集团（天津）股份有限公司 变更部分募集资金用途暨新增募集资金投资项目、 调整部分项目投资金额及延期事项的核查意见 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机构"） 作为凯莱英医药集团（天津）股份有限公司（以下简称"凯莱英"或"公司"）的保 荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所股票上市规 则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》、《上市公司募集资金监管规则》等法律和规范性文件的要求，对凯莱英医 药集团（天津）股份有限公司变更部分募集资金用途暨新增募集资金投资项目、 调整部分项目投资金额及延期情况进行了审慎核查。具体情况如下： 一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会证监许可[2020]1912 号文《关于核准凯莱英医药 集团（天津）股份有限公司非公开发行股票的批复》核准，公司于 2020 年 9 月 向特定投资者发行人民币普通股（A 股）股票 10,178,731.00 股，每股发行价为 227.00 元/股，募集资金总额为人民币 2,310,57 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-041 凯莱英医药集团（天津）股份有限公司 关于调整部分 H 股募投项目实施地点、 投资金额及延期的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存在 虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日召开第四届董事会第六十四次会议，审议通过了《关于调整部分 H 股募投项目实 施地点、投资金额及延期的议案》。为提高 H 股募集资金使用效率，公司逐步进行项 目布局、稳步推进项目实施，在对相关项目的进展进行动态评估后，拟对部分 H 股募 投项目的投资金额进行调整及延期。该事项尚需提交股东大会审议批准。现将有关事 项公告如下： 一、 调整部分 H 股募投项目实施地点、投资金额及延期基本情况 单位：百万人民币 | 募投项目名称 | 变更前 | 变更前拟使 用募集资金 | 变更后 | 变更后拟使 用募集资金 | 变更前 | | 变更后 完成时 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-039 凯莱英医药集团（天津）股份有限公司 第四届监事会第五十一次会议决议公告 本公司及全体监事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）第四届监事会 第五十一次会议通知于 2025 年 6 月 27 日以电子邮件及书面报告等形式发送给各 位监事，会议于 2025 年 7 月 4 日以通讯方式召开。公司应到监事 3 名，实到监 事 3 名，会议由公司监事会主席智欣欣女士召集，会议的召集和召开符合《公司 法》及相关法律、法规以及《公司章程》的有关规定。 二、 监事会会议审议情况 会议采用通讯方式进行了表决，经全体监事审议并表决，通过了如下决议： 1、审议通过了《关于变更部分募集资金用途暨新增募集资金投资项目、调 整部分项目投资金额及延期的议案》 经审核，监事会认为：公司本次变更部分募集资金用途暨新增募集资金投资 项目，并调整部分募投项目投资金额及项目延期事项是公司出于长远发展战略做 出的慎重决策，有利于提高募集资金使用效率，符合公司及全体 ...

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, WuXi AppTec, Asymchem Laboratories, Hangzhou Tigermed Consulting, and APT Medical [6][32] - The report also maintains an "Outperform" rating for H-Shares including PATEO, Hansoh Pharmaceutical Group, Innovent Biologics, WuXi XDC Cayman, Luye Pharma Group, and BeiGene [6][32] Core Insights - The commercial insurance innovative drug list is expected to be released soon, which is anticipated to improve the domestic market significantly [33] - The National Healthcare Security Administration and National Health Commission have released measures to support the high-quality development of innovative drugs, focusing on high-innovation drugs with significant clinical value [33] - The pharmaceutical sector underperformed the market in June 2025, with the Shanghai Composite Index rising by 2.9% while the SW Pharma Bio index rose by only 0.7% [34] - The Hang Seng Healthcare sector outperformed the market with an increase of 8.4% in June 2025, while the U.S. S&P Healthcare Select Sector underperformed with a rise of only 1.9% [35] Summary by Sections - **Investment Highlights**: Continuous positive outlook for innovative drugs and industry chain, with specific A-Shares and H-Shares recommended for investment [32][6] - **Market Performance**: In June 2025, the pharmaceutical sector's performance was weak compared to the overall market, ranking 19th among Shenwan primary industries [34] - **Sub-sector Analysis**: The best-performing sub-sectors included medical services (+4.8%), chemical preparations (+0.8%), and chemical raw materials (+0.5%) [34][20] - **Stock Performance**: Top gainers in the pharmaceutical sector included Zhejiang Anglikang Pharmaceutical (+146.4%) and Hubei Huaqiang High-Tech Co., Ltd. (+67.4%), while top losers included Kexing Biopharm Co., Ltd. (-28.7%) [34][23]

Summary of Conference Call Records Industry Overview - The innovative drug industry chain is gradually stabilizing and recovering, with CXO orders rebounding since last year, leading to strong mid-year performance in key segments [1][2][3] - The overall trend for the pharmaceutical sector in Q2 2025 is positive, particularly in innovative drugs and their supply chains, despite recent market fluctuations [2][3] Key Companies and Performance - **Hengrui, Huadong, and China Biopharmaceutical** are expected to achieve double-digit growth in Q2 and for the entire year [1][6] - **WuXi AppTec** aims for a revenue target of 43 billion, with an expected growth of over 15% and faster net profit growth; **WuXi AppTec's** revenue growth is projected at over 35% for the year [1][11] - **Kelaiying** anticipates a revenue growth of over 15% for the year, while **Kanglong Huacheng** expects around 10% growth in revenue and profit for Q2 [1][11][13] - **BaiPuSi and Haoyuan Pharmaceutical** are performing well, with most companies expecting revenue growth of over 20% [1][15] Market Catalysts - Recent adjustments in medical insurance policies and industry conferences (WCLC, ESMO, Ash) are seen as potential catalysts for growth in the innovative drug sector [1][7][9] - The upcoming medical insurance negotiations and directory adjustments are expected to be significant driving forces in the second half of the year [9][10] Investment Opportunities - Despite a recent decline in market sentiment, large-cap companies like **BaiJi, Hengrui, XinDa, Kangfang, and Shiyao** are recommended for investment, along with smaller companies like **Dizhe and Yifangzejin** [10] - The CXO and upstream sectors are highlighted as key investment areas, with strong performance expected due to improved orders and geopolitical factors [19][20] Sector Performance - The medical device sector is still in a clearing inventory phase, with some companies showing good growth, particularly in overseas markets [17][18] - The OTC and traditional Chinese medicine sectors have not shown significant improvement but may see recovery in the second half of the year [5][18] Future Outlook - The overall outlook for the second half of 2025 remains optimistic, with expectations of continued growth in the innovative drug sector and supportive external factors [9][24] - The domestic financing environment is expected to improve, with a notable increase in activity anticipated in the latter half of the year [26][38] Conclusion - The innovative drug industry chain, particularly the CXO segment, is positioned for strong growth, supported by favorable market conditions and strategic company performances. Investors are encouraged to focus on key players within this sector for potential opportunities.

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a net value increase of 1.77% recently and a year-to-date return of 8.30% [1] - The fund's recent one-month return is 0.30%, with a six-month return of 8.30%, ranking 628 out of 1722 in its category for both periods [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and has a total scale of 15.613 billion yuan as of March 31, 2025 [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at various financial institutions [2]

Group 1 - The CRO concept stocks experienced a partial surge, with Lingkang Pharmaceutical (603669) hitting the daily limit up [1] - Baicheng Pharmaceutical (301096), Kangpeng Technology, Zhaoyan New Drug (603127), and Kailaiying (002821) also saw increases [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook for the sector compared to the overall market performance [23]. Core Insights - The pharmaceutical sector experienced a decline of 4.4% this week, underperforming the Shanghai Composite Index, which fell by 0.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 28.7 times PE (2025E), ranking it 5th among 31 sub-industries [5][10]. - Recent policies from the National Medical Products Administration (NMPA) aim to support the development of high-end medical devices and accelerate the clinical review process for innovative drugs [12]. - Shengnuo Biopharma forecasts a significant profit increase for H1 2025, with expected net profit ranging from 77.03 million to 94.14 million yuan, marking a year-on-year growth of 253.54% to 332.10% [13]. Market Performance - The pharmaceutical and biotechnology index ranked 29th out of 31 sub-industries this week, with various segments showing declines, including chemical preparations (-5.7%) and medical devices (-3.7%) [2][5]. - The report highlights the strong growth in product revenue and licensing deals in the innovative drug sector over the past three years, with a focus on companies expected to release major products and those involved in the CXO industry [12]. Key Events - The NMPA has approved measures to encourage the innovation of high-end medical devices, including optimizing special approval processes and enhancing regulatory frameworks [12]. - The NMPA has also proposed a 30-day review process for clinical trial applications of innovative drugs, aimed at improving the efficiency of drug development [12].

一、股东大会审议通过权益分派方案情况 度权益分派方案。具体方案为：以分配方案未来实施时股权登记日享有利润分配 权的股本总额为基数，拟向全体股东每 10 股派发现金股利人民币 11 元（含税）， 不送红股，不以资本公积金转增股本。公司剩余未分配利润留待以后年度分配。 本次利润分配方案实施时，如因新增股份上市、股份回购、库存股完成股权激励 过户、回购注销等原因使得享有利润分配权的股份总额发生变动，公司将按照分 配比例固定的原则对分配总金额进行相应调整。 股变更为 333,040,460 股，系公司回购注销 2020 年限制性股票激励计划预留授 予离职激励对象 1,680 股股份所致，具体内容详见公司 2025 年 5 月 27 日刊登于 《中国证券报》、 证券代码：002821 证券简称：凯莱英 公告编号：2025-037 凯莱英医药集团（天津）股份有限公司 关于 2024 年年度权益分派实施的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示 权益分派方案已获公司2024年度股东大会审议通过。本次可参与利润分配的A股 总股本为331,597,760股（以 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-037 凯莱英医药集团（天津）股份有限公司 特别提示 1、凯莱英医药集团（天津）股份有限公司（以下简称"公司"）2024年度 权益分派方案已获公司2024年度股东大会审议通过。本次可参与利润分配的A股 总股本为331,597,760股（以公司目前A股总股本333,040,460为基数，扣除公司 回购专用账户中的回购股份总数1,442,700股）,公司本次A股现金分红共计 364,757,536.00元（含税）。 2、因公司回购账户股份不参与分红，本次权益分派实施后，根据股票市值 不变原则，实施权益分派前后公司A股总股本保持不变，现金分红总额分摊到每 一股的比例将减小。本次权益分派按公司总股本折算的每股现金红利为 1.0952349元/股（计算结果直接截取小数点后七位，不四舍五入）。本次权益分 派实施后的除权除息参考价=除权除息日前一交易日收盘价-按公司总股本折算 每股现金分红金额=股权登记日收盘价-1.0952349元/股。 一、股东大会审议通过权益分派方案情况 1、2025 年 6 月 11 日公司召开 2024 年度股东大会，审议通过了 202 ...